All In Biotech

Drug Trial Radar · NCT05865535

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jun 13, 2023

Primary completion

Aug 11, 2026

Study completion Sep 25, 2026

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Conditions

  • Cachexia

Interventions

  • AV-380Biological

    AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of adverse events (AEs)Time frame: From enrollment to the last follow-up visit approximately 60-days post dose
  2. ToxicityTime frame: While receiving study drug (up to 4 months)
  3. Laboratory AbnormalitiesTime frame: From enrollment to the last follow-up visit approximately 60-days post dose.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Cancer and Blood Specialty Clinic

    Lakewood, California

  • Hoag Memorial Hospital

    Newport Beach, California

  • Hartford Hospital

    Hartford, Connecticut

  • Advent Health Orlando Hospital

    Orlando, Florida

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Astera Cancer Care

    East Brunswick, New Jersey

  • New York Cancer And Blood Specialists

    Shirley, New York

  • Oregon Health and Science University

    Portland, Oregon

  • MUSC Hollings Cancer Center

    Charleston, South Carolina

  • Vanderbilt University Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • Community Clinical Trials

    Kingwood, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.